Taiwan Continuous Glucose Monitoring (CGM) Market Size, Share, Opportunities, And Trends By Application (Diabetic Patients, Critical Patients), By End User Industry (Hospitals, Diagnostic Centers and Clinics, Home care), By Gender (Male, Female), By Age (Greater than 20 years, Less than 20 years), And By Type (Real-time CGM, Intermittently Scanned CGM) - Forecasts From 2025 To 2030

Taiwan Continuous Glucose Monitoring (CGM) Market Size:

The Taiwanese continuous glucose monitoring (CGM) Market is projected to grow at a CAGR of 17.73% over the forecast period, increasing from US$9.034 million in 2025 to reach US$20.435 million by 2030.

Continuous glucose monitoring (CGM) is a wearable medical device designed to monitor continuously blood sugar levels. continuously, catering to It is used by individuals with both type 1 and type 2 diabetes. In Taiwan, the CGM market is experiencing significant growth, driven by various factors.

Key drivers include the growing prevalence of diabetes, a heightened awareness and acceptance of CGM technology, robust government support, and policy initiatives. Additionally, the increasing disposable income and a growing focus on healthcare contribute to the market's upward trajectory. CGM devices, like other innovative monitoring tools, play a pivotal role in transforming patient care. They empower "remote" patients, allowing them to leverage monitoring devices and wearable sensors, such as continuous glucose monitoring systems (CGMS).

These devices not only collect crucial healthcare data but also enable the transmission of this information to relatives and healthcare providers. This facilitates timely interventions, potentially reducing the need for hospital visits. Globally, MicroTech CGMS has proven instrumental in aiding thousands of patients through remote monitoring.  

In Taiwan, numerous companies, such as Bionime, are making significant strides in the CGM market. In October 2023, Bionime Corporation received approval from the TFDA (Taiwan FDA). The iFree Continuous Glucose Monitoring System (iFree CGM) is for detecting glycemic trends and managing glucose levels. It can help to detect hyperglycemia and hypoglycemia. iFree CGM can benefit not only diabetes patients but also people who need it for glucose management. 

 The impaired glucose tolerance (IGT) estimates (20-79 y), the age-adjusted comparative prevalence of IGT in Taiwan was 11.5% in 2021, likely to be 12.4 % in 2030, and 12.8 % in 2045.  Due to this, the CGM market in Taiwan is poised for immense growth, and capitalizing on these driving forces is imperative for sustained expansion. This strategic approach not only ensures market growth but also plays a vital role in enhancing diabetes management for thousands of individuals in Taiwan.

What are the drivers of the Taiwan Continuous Glucose Monitoring Market?

• Rising diabetic cases in Taiwan propel the demand 

The prevalence of Type 2 diabetes in Taiwan has experienced a significant surge over the past few decades. This alarming increase is primarily attributed to unhealthy lifestyles characterized by diets high in sugar and fat, coupled with insufficient physical activity. In 2021, the number of individuals aged 20-79 with diabetes was 2,457.2 (in 1,000s), a figure projected to escalate to 2,979.4 (in 1,000s) by 2030, and 3,030.7 (in 1,000s) by 2045 as per estimates from the International Diabetes Federation.  

While increased awareness and improved diagnostics have contributed to higher detection rates, the numbers are expected to rise further due to urbanization, an aging population, and persistently unhealthy lifestyles. Traditionally, diabetes management in Taiwan heavily relied on finger-prick glucometers. However, CGM Continuous Glucose Monitoring has emerged as a transformative tool, providing real-time glucose data and trend analysis. This not only facilitates better glycemic control but also enhances the overall quality of life for individuals managing diabetes.

The growing recognition of these advantages, coupled with marketing efforts by CGM manufacturers, is propelling the adoption of CGM technology in Taiwan. This shift in approach holds promise for improving diabetes management outcomes amidst the rising challenges posed by the escalating rates of Type 2 diabetes in the country.

• Better healthcare coverage by pharmacies to surge growth.

In Taiwan, pharmacies are seen as a key instrument for improving healthcare coverage. Technology tools have been implemented in the pharmaceutical sector. Companies who participate in the "Beyond the Pills" campaign add digital platforms to their drug treatment programs to encourage follow-up and guarantee treatment continuation. One of the businesses utilizing the Beyond the Pills method to treat diabetes is Roche. MySugr is a digital platform used by the pharmaceutical business to control diabetes. To meet unmet requirements, Roche can do so by providing openly available patient solutions. It seeks to assist diabetics in improving their quality of life by helping them spend more time inside their optimum glucose target range.

What are the trends shaping the Taiwan Continuous Glucose Monitoring Market?

• Increase in education, training, and recognition related to diabetes patients.
• Rising number of hospitals, diagnostic centers, clinics, and home care.
• CGM sensors are a prominent market shareholder. Throughout the projected period, technological developments to increase sensor accuracy are anticipated to fuel market expansion. CGM has been a popular substitute for portable finger-prick glucometers providing convenience to diabetic patients which will upsurge the market in Taiwan. 

Taiwan Continuous Glucose Monitoring (CGM) Market is segmented and analyzed as follows:

• Taiwan Continuous Glucose Monitoring (CGM) Market By Application

The Taiwanese continuous glucose monitoring market is segmented by application into diabetes patients and critical patients. Taiwan’s market for CGM for diabetics has been expanding rapidly due to several factors. An aging population, altered eating patterns, and lifestyle changes have all contributed to the rising incidence of diabetes, which has increased demand for sophisticated glucose monitoring devices. For instance, according to the National Development Council, the number of elderly people is increasing rapidly in the country. In 2017, the number of elderly population was 3,268 thousand persons, which increased to 4,086 thousand people in 2022, and 4,297 thousand people in 2023., the number of elderly people increased to 4,297 thousand persons. Elderly people are at high risk of developing diseases such as diabetes. Hence, the rising number of the elderly population is anticipated to impact the market for continuous glucose monitoring in the projected period. 

Many other factors impact the Taiwan market for CGM among diabetic patients. The adoption of CGM technology is impacted by the quality and accessibility of Taiwan’s healthcare infrastructure. T Economic factors, including GDP growth and healthcare spending, influence the purchasing power of consumers and healthcare providers. is influenced by economic factors, including GDP growth and healthcare spending. Additionally, the rising per capita income is also expected to impact the market positively in the projected period. 

For instance, as per the Ministry of Foreign Affairs, Republic of China (Taiwan), the nominal GDP of Taiwan was US$653 billion in 2022. and As per the International Monetary Fund, the nominal GDP will increase to US$802.96 billion in 2024. Hence, the above factors are anticipated to influence the market for the diabetes patient segment in the CGM market. Moreover, the increasing number of diabetes patients is anticipated to propel the market for continuous glucose monitoring (CGM) for diabetes patients in the projected period.

Key developments in the Taiwan Continuous Glucose Monitoring Market:

The market leaders for the Taiwan Continuous Glucose Monitoring Market are Abbott Laboratories, Medtronic plc, Roche Diabetes Care, Inc., Tandem Diabetes Care, Inc., ARKRAY Inc., Taidoc Technology Corporation, Bionime Corporation, Novo Nordisk A/S

 The key players in the market implement growth strategies such as product launches, mergers, acquisitions, etc. to gain a competitive advantage over their competitors. For Instance,

•  In October 2023, Bionime Corporation announced that its continuous glucose meter (CGM) had been approved by Taiwan's Ministry of Health and Welfare for marketing. Bionime's CGM was the first in Taiwan with TFDA clearance. The company said that in addition to continuing to build its own automated production facilities for CGM products, the company would enter into licensing negotiations with multinational companies.

Taiwan Continuous Glucose Monitoring (CGM) Market Scope:

Report Metric	Details
Taiwan Continuous Glucose Monitoring (CGM) Market Size in 2025	US$9.034 million
Taiwan Continuous Glucose Monitoring (CGM) Market Size in 2030	US$20.435 million
Growth Rate	CAGR of 17.73%
Study Period	2020 to 2030
Historical Data	2020 to 2023
Base Year	2024
Forecast Period	2025 – 2030
Forecast Unit (Value)	USD Million
Segmentation	Application End-User Industry Gender Age Type
List of Major Companies in Taiwan Continuous Glucose Monitoring (CGM) Market	Abbott Laboratories Medtronic plc Roche Diabetes Care, Inc. Tandem Diabetes Care, Inc. ARKRAY Inc.
Customization Scope	Free report customization with purchase

 

Taiwan's Continuous Glucose Monitoring Market is analyzed into the following segments:

• By Application
  • Diabetes Patients
  • Critical Patients
• By End-User Industry
  • Hospitals
  • Diagnostic Centers & Clinics
  • Home Care
• By Gender
  • Male
  • Female
• By Age 
  • Greater than 20 years
  • Less than 20 years
• By Type
  • Real-time CGM
  • Intermittently Scanned CGM

Our Best-Performing Industry Reports:

• Blood Pressure Monitoring Devices Market
• Smart Medical Device Market
• Refurbished Medical Equipment Market

---

1. INTRODUCTION

1.1. Market Overview

1.2. Market Definition

1.3. Scope of the Study

1.4. Market Segmentation

1.5. Currency

1.6. Assumptions

1.7. Base and Forecast Years Timeline

1.8. Key benefits for the stakeholders

2. RESEARCH METHODOLOGY  

2.1. Research Design

2.2. Research Process

2.3. Data Validation

3. EXECUTIVE SUMMARY

3.1. Key Findings

3.2. Analyst View

4. MARKET DYNAMICS

4.1. Market Drivers

4.2. Market Restraints

4.3. Porter’s Five Forces Analysis

4.3.1. Bargaining Power of Supplier

4.3.2. Bargaining Power of Buyers

4.3.3. Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4.  Industry Value Chain Analysis

5. TAIWAN CONTINUOUS GLUCOSE MONITORING (CGM) BY APPLICATION

5.1. Introduction

5.2. Diabetes Patients

5.3. Critical Patients

6. TAIWAN CONTINUOUS GLUCOSE MONITORING (CGM) BY END-USER INDUSTRY

6.1. Introduction

6.2. Hospitals

6.3. Diagnostic Centers & Clinics

6.4. Home Care

7. TAIWAN CONTINUOUS GLUCOSE MONITORING (CGM) BY GENDER

7.1. Introduction

7.2. Male

7.3. Female

8. TAIWAN CONTINUOUS GLUCOSE MONITORING (CGM) MARKET BY AGE 

8.1. Introduction

8.2. Greater than 20 years

8.3. Less than 20 years

9. TAIWAN CONTINUOUS GLUCOSE MONITORING (CGM) MARKET BY TYPE

9.1. Introduction

9.2. Real-time CGM

9.3. Intermittently Scanned CGM

10. COMPETITIVE ENVIRONMENT AND ANALYSIS

10.1. Major Players and Strategy Analysis

10.2. Emerging Players and Market Lucrativeness

10.3. Mergers, Acquisitions, Agreements, and Collaborations

10.4. Competitive Dashboard

11. COMPANY PROFILES

11.1. Abbott Laboratories

11.2. Medtronic plc

11.3. Roche Diabetes Care, Inc.

11.4. Tandem Diabetes Care, Inc.

11.5. ARKRAY Inc.

11.6. Taidoc Technology Corporation

11.7. Bionime Corporation (Ypsomed AG)

11.8. Novo Nordisk A/S

Abbott Laboratories

Medtronic plc

Roche Diabetes Care, Inc.

Tandem Diabetes Care, Inc.

ARKRAY Inc.

Taidoc Technology Corporation

Bionime Corporation (Ypsomed AG)

Novo Nordisk A/S